|
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi:10.3322/caac.20138 2. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol. 2011 Nov;123(2):200-4. doi:10.1016/j.ygyno.2011.06.038 3. Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009 Sep;29(9):3511-36. 4. Arab M, Khayamzadeh M, Mohit M, Hosseini M, Anbiaee R, Tabatabaeefar M, et al. Survival of ovarian cancer in Iran: 2000-2004. Asian Pac J Cancer Prev. 2009 Oct-Dec;10(4):555-8. 5. Born HJ, Kühnert E, Halberstadt E. [Diagnosis of fetal ovarian cysts. Follow-up or differential diagnosis?]. Ultraschall Med. 1997 Oct; 18(5):209-13. [Article in German] 6. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, et al. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2566-71. 7. Horne HN, Sherman ME, Garcia-Closas M, Pharoah PD, Blows FM, Yang XR, et al. Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression. Breast Cancer Res Treat. 2014 Jan; 143(1):181-7. doi:10.1007/s10549-013-2771-z 8. Ali MM, Vaidya V. Vitamin D and cancer. J Can Res Ther. 2007; 3: 225-30. doi:10.4103/0973-1482.38998 9. Pawlik P, Mostowska A, Lianeri M, Sajdak S, Kędzia H, Jagodzinski PP. Folate and choline metabolism gene variants in relation to ovarian cancer risk in the Polish population. Mol Biol Rep. 2012 May;39(5):5553-60. doi:10.1007/s11033-011-1359-0 10. Cook J. Family history of ovarian cancer. Obstetrics, Gynaecology and Reproductive Medicine. 2002; 12(1): 47-51. http://dx.doi.org/10.1054/cuog.2001.0232 11. Li Y, Liang J, Kang S, Dong Z, Wang N, Xing H, et al. E-cadherin gene polymorphisms and haplotype associated with the occurrence of epithelial ovarian cancer in Chinese. Gynecol Oncol. 2008 Feb;108(2):409-14. 12. Gallin WJ, Sorkin BC, Edelman GM, Cunningham BA. Sequence analysis of a cDNA clone encoding the liver cell adhesion molecule, L-CAM. Proc Natl Acad Sci U S A. 1987 May; 84(9):2808-12. 13. Deng QW, He BS, Pan YQ, Sun HL, Xu YQ, Gao TY, et al. Roles of E-cadherin (CDH1) genetic variations in cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(8):3705-13. 14. Cook LS, Kamb ML, Weiss NS. Perineal powder exposure and the risk of ovarian cancer. Am J Epidemiol. 1997 Mar; 145(5): 459-65. 15. Bukholm IK, Nesland JM, Børessen-Dale AL. Re-expression of E-cadherin, α-catenin and β-catenin, but not of γ-catenin, in metastatic tissue from breast cancer patients. The Journal of Pathology. 2000; 190(1): 15-19. doi:10.1002/(SICI)1096-9896(200001)190:1<15::AID-PATH489>3.0.CO;2-L 16. Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol. 2003;19:207-35. 17. Berx G, Staes K, van Hengel J, Molemans F, Bussemakers MJ, van Bokhoven A, et al. Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics. 1995 Mar; 26(2): 281-9. 18. Rietmacher D, Brinkmann V, Birchmeier CA. A targeted mutation in the mouse E-cadherin gene results in defective preimplantation development. Proc Natl Acad Sci USA. 1995; 92(3):855-59. 19. Larue L, Ohsugi M, Hirchenhain J, Kemler R. E-cadherin null mutant embryos fail to form a trophectoderm epithelium. Proc Natl Acad Sci U S A. 1994 Aug; 91(17):8263-7. 20. Donna A, Crosignani P, Robutti F, Betta PG, Bocca R, Mariani N, et al. Triazine herbicides and ovarian epithelial neoplasms. Scand J Work Environ Health. 1989 Feb;15(1):47-53. 21. Fleming TP, Javed Q, Hay M. Epithelial differentiation and intercellular junction formation in the mouse early embryo. Dev Suppl. 1992:105-12. 22. Barth AI, Näthke IS, Nelson WJ. Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signaling pathways. Curr Opin Cell Biol. 1997 Oct;9(5):683-90. 23. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997 Mar; 275(5307):1787-90. 24. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. Science. 2000 Mar; 287(5458):1606-9. 25. Efstathiou JA, Liu D, Wheeler JM, Kim HC, Beck NE, Ilyas M, et al. Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. Proc Natl Acad Sci U S A. 1999 Mar; 96(5):2316-21. 26. Risinger JI, Berchuck A, Kohler MF, Boyd J. Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet. 1994 May; 7(1):98-102. 27. Lin HJ, Tsai FJ, Hung P, Chen WC, Chen HY, Fan SS, et al. Association of E-cadherin gene 3'-UTR C/T polymorphism with primary open angle glaucoma. Ophthalmic Res. 2006;38(1):44-8. 28. Keirsebilck A, Van Hoorde L, Gao Y, De Bruyne G, Bruyneel E, Vermassen P, et al. Mechanisms of downregulation of transfected E-cadherin cDNA during formation of invasive tumors in syngeneic mice. Invasion Metastasis. 1998;18(1):44-56. 29. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004 May; 164(5):1511-8. 30. Wu M, Huang Sh, Chang Y, Lin M, Shun CT, Chang M, et al. Association of the -160 C→A promoter polymorphism of E-cadherin gene with gastric carcinoma risk. American Cancer Society. 2002; 94(5): 1443-8. 31. Chu CM, Chen CJ, Chan DC, Wu HS, Liu YC, Shen CY, et al. CDH1 polymorphisms and haplotypes in sporadic diffuse and intestinal gastric cancer a case-control study based on direct sequencing analysis. World J Surg Oncol. 2014; 12: 80. doi:10.1186/1477-7819-12-80 32. Tsukino H, Kuroda Y, Nakao H, Imai H, Inatomi H, Kohshi K, et al. E-cadherin gene polymorphism and risk of urothelial cancer. Cancer Lett. 2003 May; 195(1):53-8. 33. Machado JC, Soares P, Carneiro F, Rocha A, Beck S, Blin N, et al. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest. 1999 Apr;79(4):459-65. 34. Suzuki H, Komiya A, Emi M, Kuramochi H, Shiraishi T, Yatani R, et al. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosomes Cancer. 1996 Dec;17(4):225-33. 35. Wu HC, Lai MT, Wu CI, Chen HY, Wan L, Tsai FJ, et al. E-cadherin gene 3'-UTR C/T polymorphism is associated with prostate cancer. Urol Int. 2005;75(4):350-3. 36. Tsai FJ, Wu HC, Chen HY, Lu HF, Hsu CD, Chen WC. Association of E-cadherin gene 3'-UTR C/T polymorphism with calcium oxalate stone disease. Urol Int. 2003;70(4):278-81. 37. Chang Z, Zhou H, Liu Y. Promoter methylation and polymorphism of E-cadherin gene may confer a risk to prostate cancer: a meta-analysis based on 22 studies. Tumour Biol. 2014 Oct; 35(10):10503-13. doi:10.1007/s13277-014-2323-0 38. Richards FM, McKee SA, Rajpar MH, Cole TR, Evans DG, Jankowski JA, et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet. 1999 Apr;8(4):607-10. 39. Deng QW, He BS, Pan YQ, Sun HL, Xu YQ, Gao TY, et al. Roles of E-cadherin (CDH1) genetic variations in cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(8):3705-13.
|
